Table of contents

Poster Presentation

• Transient regulatory T-cell (Treg) depletion with IL-2 diphtheria toxin fusion protein enhances clearance of acute myeloid leukemia by haploidentical natural killer (NK) cells (7 November, 2013)

  Veronika Bachanova, Sarah Cooley, Todd Defor, Michael R Verneris, Bin Zhang, David McKenna, Julie Curtsinger, Angela Panoskaltsis-Mortari, Dixie Lewis, Keli Hippen, Philip McGlave, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller
• Adoptive transfer of IL13Rα2-specific T cells for the treatment of glioblastoma: building on clinical achievements with second-generation CARs (7 November, 2013)

  Christine E Brown, Renate Starr, Araceli Naranjo, Brenda Aguilar, Wen-Chung Chang, Julie Ostberg, Charles Warden, Yate-Ching Yuan, Massimo D'Apuzzo, Michael E Barish, Behnam Badie, Michael C Jensen, Stephen J Forman
• Immediate triggering of 4-1BB co-stimulation during initiation of tumor-infiltrating lymphocyte (TIL) expansion from melanoma tumors accelerates CD8+ T-cell outgrowth and tumor specificity (7 November, 2013)

  Jessica Chacon, Shari Pilon-Thomas, Amod Sarnaik, Patrick Hwu, Laszlo Radvanyi
• Bioengineering cytotoxic T cells to target opportunistic fungal infection (7 November, 2013)

  Pappanaicken Kumaresan, Pallavi R Manuri, Nathaniel Albert, Brian Rabinovich, Simon Olivares, Sourindra N Maiti, Helen Huls, Dean A Lee, Dimitrios Kontoyiannis, Laurence J Cooper
• Optimization of ex vivo expansion of HER2 specific polyfunctional Th1/Th17 cells from HER2 vaccine primed PBMC (7 November, 2013)

  Yushe Dang, Lupe Salazar, Jennifer Childs, Doreen Higgins, Mary L Disis
• Induction and isolation of tumor antigen-specific CD4+ T lymphocytes using sorting signal directed MHC class-II expression (7 November, 2013)

  Christian Ellinger, Carina Wehner, Susanne Wilde, Dolores J Schendel, Slavoljub Milosevic
• Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia (7 November, 2013)

  Loren Fast, John Reagan, Peter Quesenberry
• Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy (7 November, 2013)

  Marie-Andrée Forget, Shruti Malu, Hiu Liu, Christopher Toth, Sourindra Maiti, Charuta Kale, Chantale Bernatchez, Helen Huls, Ena Wang, Patrick Hwu, Laurence J Cooper, Laszlo G Radvanyi
• Pre-T cell receptor for improved expansion of TCR alpha disrupted T cells (7 November, 2013)

  Roman Galetto, Céline Lebuhotel, Laurent Poirot, Cécile Schiffer-Mannioui, Sylvain Arnould, Julianne Smith, Andrew Scharenberg
• Improved affinity AFP-specific T cell receptor for hepatocellular carcinoma (7 November, 2013) Free

  Andrew B Gerry, Nicholas J Pumphrey, Roslin Y Docta, Joanna E Brewer, Alan D Bennett, Bent K Jakobsen
• “First AID” for T cell adoptive transfer: TCR affinity maturation by somatic hypermutation (7 November, 2013)

  Yosi M Gozlan, Esther Tzehoval, Lea Eisenbach
• CD28 co-stimulation induced Lck signaling is important for survival and antigen-specific functionality of re-directed T cells (7 November, 2013)

  Pratiksha Gulati, Petra Schuberth, Christoph Renner, Christian Munz, Ulf Petrausch
• Discovery of CD8 T cell epitopes in Merkel cell polyomavirus through combinatorial encoding with MHC multimers (7 November, 2013) Free

  Rikke Lyngaa, Natasja W Pedersen, David Schrama, Charlotte A Thrue, Özcan Met, Dafina Ibrani, Per thor Straten, Paul Nghiem, Jürgen C Becker, Sine R Hadrup
• Augmenting adoptive T cell therapy through universal chimeric costimulators (7 November, 2013)

  Ken-ichi Hanada, Prachi Bagadia, Qiong Wang, Kayla Griffith, James Yang
• Adoptive transfer of tumor infiltrating lymphocytes for metastatic cervical cancer (7 November, 2013)

  Christian S Hinrichs, Sanja Stevanovic, Lindsey Draper, Michelle Langhan, Mark Dudley, John Wunderlich, Steven A Rosenberg
• Development of chimeric antigen receptor-redirected T cell therapy targeting L1-CAM in ovarian cancer (7 November, 2013)

  Hao Hong, Christine Brown, Stephen J Forman, Michael Jensen
• IL-12 primed CD8+ T-cells possess enhanced persistence and anti-tumor efficacy because of greater IL-7 responsiveness (7 November, 2013)

  C Bryce Johnson, Bennett R May, Colleen A Cloud, Mark P Rubinstein, David J Cole
• Chimeric antigen receptors (CARs) incorporating mutations in the IgG4 Fc spacer region to eliminate Fc receptor recognition results in improved CAR T cell persistence and anti-tumor efficacy (7 November, 2013)

  Mahesh Jonnalagadda, Armen Mardiros, Lauren Hoffman, Alyssa Bernanke, Wen-Chung Chang, William Bretzlaff, Renate Starr, Xiuli Wang, Julie Ostberg, Christine Brown, Stephen J Forman
• Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy (7 November, 2013)

  Sander Kelderman, Bianca Heemskerk, Mireille Toebes, Marit van Buuren, Nienke van Rooij, Laura Bies, Lorenzo Fanchi, Lothar Germeroth, Pia Kvistborg, Ton Schumacher
• Multimeric forms of CD40 ligand (CD40L), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L), CD27L/CD70, and other TNFSFs as tools for adoptive cell therapy (7 November, 2013)

  Richard S Kornbluth
• Enhanced glycolytic metabolism is associated with exhaustion and poor antitumor efficacy in a xenograft model of chimeric antigen receptor T cell therapy for sarcoma (7 November, 2013)

  Adrienne H Long, Rimas J Orentas, Crystal L Mackall
• GUCY2C-targeted chimeric antigen receptor expressing T cells extend survival in a therapeutic mouse model of metastatic colorectal cancer (7 November, 2013)

  Michael S Magee, Adam E Snook, Adam R Hersperger, Glen P Marszalowicz, Scott A Waldman
• The role of transcription factor Runx2 in tumor infiltrating T cells (7 November, 2013)

  Rina Mbofung, Weiyi Peng, Chengwen Liu, Chunyu Xu, Shruti Malu, Yan Yang, Wencai Ma, Zhiqiang Wang, Willem Overwijk, Eric Davis, Brendan Lee, Patrick Hwu
• In vitro and in vivo priming of T cells using dendritic cells loaded with internal cell localization signals fused cancer testis antigens (7 November, 2013)

  Slavoljub Milosevic
• Development of an adoptive cell therapy protocol with tumor-infiltrating lymphocytes and intermediate-dose interleukin-2 therapy (7 November, 2013)

  Linh T Nguyen, Marcus O Butler, Pei Hua Yen, Jessica Nie, Michael Pniak, Alisha R Elford, Anthony M Joshua, David Hogg, Danny Ghazarian, Ayman Al-Habeeb, Alexandra M Easson, Wey L Leong, David R McCready, Michael Reedijk, Hans A Messner, Pamela S Ohashi
• Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival (7 November, 2013)

  Cary F Opel, K Dane Wittrup
• ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors (7 November, 2013)

  Rimas J Orentas, Paola Lopomo, William Babbitt, Marc Vigny, Crystal L Mackall
• Synergy between liposomal zoledronic acid and γδ T-cells in the treatment of epithelial ovarian cancer (7 November, 2013)

  Ana Catarina Parente Pereira, Hilary Shmeeda, Lynsey Whilding, Sadaf Ghaem-Maghami, Alberto Gabizon, John Maher
• Activity of dose-dense outpatient intravenous Interleukin-2 preceded by famotidine in metastatic clear cell cancer of the kidney (7 November, 2013)

  Walter Quan, Francine M Quan
• Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT (7 November, 2013)

  Aaron P Rapoport, Edward A Stadtmauer, Dan T Vogl, Brendan Weiss, Gwendolyn K Binder-Scholl, Dominic P Smethurst, Jeffrey Finklestein, Irina Kulikovskaya, Minnal Gupta, Joanna E Brewer, Alan D Bennett, Andrew B Gerry, Nick J Pumphrey, Helen K Tayton-Martin, Lilliam Ribeiro, Ashraf Z Badros, Saul Yanovich, Gorgun Akpek, Naseem Kerr, Sunita Philip, Sandra Westphal, Levine L Bruce, Bent K Jakobsen, Carl H June, Michael Kalos
• Genetically engineered lymphocytes in metastatic melanoma: TIL 1383I TCR transduced T-cells are detectable after infusion (7 November, 2013)

  Courtney Regan, Michael Nishimura, Ann Lau Clark, Kelly Moxley, Gina Scurti, Vladimir Slepushkin, Andre Roy, Kathy Schonely, Boro Dropulic, Joseph Clark
• Chimeric antigen receptor (CAR)+ T cell selection method affects transgene efficacy (7 November, 2013)

  David Rushworth, Tiejuan Mi, Simon Olivares, Rosa Santana Carrero, Ge Yang, Amer Najjar, Laurence Cooper
• A chimeric antigen receptor against prostate-specific membrane antigen, a tumor vasculature target (7 November, 2013)

  Stephen P Santoro, Soorin Kim, Dimitrios Alatzoglou, Daniel J Powell, George Coukos
• Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells (7 November, 2013)

  Cécile Schiffer Mannioui, Laëtitia Lemaire, Laurent Poirot, Agnes Gouble, Sylvain Arnould, Roman Galetto, Julianne Smith, Andrew Scharenberg
• Pre-clinical testing of malignant fibroblast activation protein-specific re-directed T cells for treatment of pleural mesothelioma (7 November, 2013)

  Petra C Schuberth, Christian Hagedorn, Shawn M Jensen, Pratiksha Gulati, Osiris Marroquin Belaunzaran, Alex Soltermann, Astrid Jüngel, Christoph Renner, Ulf Petrausch
• Quantitative single-cell characterization of CAR+ T cell effector functions (7 November, 2013) Free

  Ivan Liadi, Harjeet Singh, Gabrielle Romain, Nicolas Rey-Villamizar, Amin Merouane, Badrinath Roysam, Laurence J Cooper, Navin Varadarajan
• Whole body irradiation combined with adoptive T cell transfer results in regression of high-grade intraepithelial neoplasia and long-term persistence of tumor-specific CD8+ T cells in TRAMP mice (7 November, 2013)

  Lindsay K Ward-Kavanagh, Timothy K Cooper, Todd D Schell
• ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy (7 November, 2013) Free

  Congcong Zhang, Michael Burger, Kurt Schönfeld, Sabrina Genβler, Christiane Sahm, Sonja Naundorf, Marcus Odendahl, Paulina Nowakowska, Torsten Tonn, Manuel Grez, Joachim P Steinbach, Winfried S Wels
• MHC class I/II deficient NOG mice are useful for analysis of human T/B cell responses for human tumor immunology research (7 November, 2013)

  Tomonori Yaguchi, Asuka Kobayashi, Ikumi Katano, Yuyo Ka, Mamoru Ito, Yutaka Kawakami
• Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model (7 November, 2013) Free

  Caroline Sola, Fabien Chanuc, Ariane Thielens, Nicolas Fuseri, Yannis Morel, Mathieu Bléry, Pascale André, Eric Vivier, Robert Graziano, Francois Romagne, Cécile Bonnafous
• Targeting MICA with therapeutic antibodies for the treatment of cancer (7 November, 2013) Free

  Cécile Bonnafous, Valentine Peri, Sylvia Trichard, Ivan Perrot, Stéphanie Cornen, Ariane Thielens, Violette Breso, Yannis Morel, Benjamin Rossi, Carine Paturel, Laurent Gauthier, Mathieu Bléry
• ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer (7 November, 2013) Free

  Sara M Mangsbo, Sissela Broos, Erika Gustafsson, Christina Furebring, Niina Veitonmäki, Eva Dahlen, Per Norlen, Malin Lindstedt, Thomas Tötterman, Peter Ellmark
• Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab (7 November, 2013)

  Andres Forero, Mehdi Hamadani, Thomas Kipps, Michelle Fanale, Antonio Cuneo, Jaime Perez de Oteyza, Douglas Gladstone, Marc Andre, Naresh Bellam, Trishna Goswami, Ramy Ibrahim, Amy Schneider, Meina Liang, Steven Eck, Nairouz Elgeioushi, Ronald Herbst, Bruce D Cheson
• TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells (7 November, 2013)

  Hailing Lu, Yi Yang, Veronika Groh, Thomas Spies, Gregory Dietsch, Maura Matthews, Mary L Disis, Robert Hershberg
• Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T cell lymphomas (7 November, 2013) Free

  Anne Marie-Cardine, Nicolas Viaud, Arnaud Dujardin, Joly Rachel, Nathalie Granier, Laurent Gauthier, Cecile Bonnafous, Mathieu Blery, Carine Paturel, Armand Bensussan, Martine Bagot, Helene Sicard
• Genomic scale analysis of NK cells impact on response to IFN-α (7 November, 2013)

  Maria L Ascierto, Harvey Alter, Federica Bozzano, Antonio Picciotto, Simona Marenco, Francesco Marras, Cathy Schechterly, Davide Bedognetti, Valeria De Giorgi, Michele Sommariva, Paolo A Ascierto, Lorenzo Moretta, Ena Wang, Francesco M Marincola, Andrea De Maria
• SSX expression and function in prostate cancer (7 November, 2013)

  Jordan E Bloom, Douglas G McNeel
• Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy (7 November, 2013)

  Jie Qing Chen, Caitlin Creasy, Carlos Antonio Torres Cabala, Suhendan Ekmekcioglu, Sourindra N Maiti, Jason Roszik, Cara Haymaker, Chantale Bernatchez, Patrick Hwu, Laszlo Radvanyi
• Combined low-FOXP3+ and -CD3+tumor infiltrating lymphocytes: a signature of stage II MSS colorectal cancer at high-risk of recurrence (7 November, 2013)

  Giuseppe Di Caro, Giuseppe Celesti, Fabio Grizzi, Paolo Bianchi, Gianluca Basso, Federica Marchesi, Alberto Mantovani, Alberto Malesci, Luigi Laghi
• The CD4+/CD14+HLA-DRlo/neg ratio as a prognostic biomarker in cancer patients (7 November, 2013)

  Allan B Dietz, Michael P Gustafson, Yi Lin, Betsy LaPlant, Courtney J Liwski, Mary L Maas, Stacy C League, Philippe R Bauer, Roshini S Abraham, Matthew K Tollefson, Eugene D Kwon, Dennis A Gastineau
• Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival (7 November, 2013)

  Italia Grenga, Renee N Donahue, James L Gulley, Christopher Heery, Ravi A Madan, Jeffrey Schlom, Benedetto Farsaci
• The cancer-testis Sp17 and ASP are expressed in the ciliated hepatic foregut cysts (7 November, 2013)

  Fabio Grizzi, Sonia Di Biccari, Barbara Franceschini, Vladimir Osipov, Everardo Cobos, Maurizio Chiriva-Internati
• Programmed death-ligand 1 (PD-L1) expression in various tumor types (7 November, 2013)

  Joseph Grosso, David Inzunza, Qiuyan Wu, Jason Simon, Parul Singh, Xiaoling Zhang, Therese Phillips, Pauline Simmons, John Cogswell
• Multiplexed characterization of cancer immune response in FFPE biopsies - initial performance of a new approach (7 November, 2013) Free

  Chichung Wang, Rebecca King, Michael Feldman, Clifford Hoyt
• Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer (7 November, 2013) Free

  Seema Dubey, Sumedha Gunewardena, Peter Van Veldhuizen, J Brantley Thrasher, Dev Karan
• Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination (7 November, 2013)

  Nobukazu Komatsu, Xiaoliang Pang, Hiromitsu Araki, Yoshiro Koda, Kimiko Soejima, Tetsuro Sasada, Kosuke Tashiro, Satoru Kuhara, Kyogo Itoh
• Molecular analysis of antigen presentation machinery in circulating tumor cells from renal cell carcinoma and prostate cancer (7 November, 2013)

  Joshua M Lang, Jacob T Tokar, Jamie Sperger, Benjamin P Casavant, Scott M Berry, Lindsay N Strotman, David J Beebe
• Reciprocal expression of tumour-associated carbohydrate antigens (Tn/sTn) and nuclear factor-B serves as an indicator of the prognosis of oral squamous cell carcinoma (7 November, 2013) Free

  Chi-Yu Lin, Shin Nieh, Jacqueline Whang-Peng, Jaulang Hwang
• Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer (7 November, 2013)

  Sasha E Stanton, Jianning Mao, John Ladd, Lauren Rastedder, Ekram Gad, Samir Hanash, Mary L Disis
• Validation of an image analysis algorithm to quantify leukocyte populations using whole slide image analysis (7 November, 2013)

  Anthony J Milici, David Young, Steven J Potts, Holger Lange, Nicholas D Landis, Erik R Hagendorn, Sherri A Saturley, Lisa Hall, Joseph S Krueger
• Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy (7 November, 2013)

  Poonam Molli, Inga Malinina, Anu Wallecha
• Direct analysis of HLA/HER-2 peptide epitopes (7 November, 2013)

  Andrea Patterson, Wilfried Bardet, Ken Jackson, Jon Weidanz, William Hildebrand
• Genetic inference of immune responsiveness of melanoma cancer patients to TIL therapy (7 November, 2013)

  Michele Sommariva, Foo Cheung, Jinguo Chen, Rongye Shi, Ling Zhang, Richard Morgan, Davide Bedognetti, Valeria De Giorgi, Maria L Ascierto, Steven A Rosenberg, Francesco M Marincola, Ena Wang
• Tumor-infiltrating T lymphocyte clonality predicts prognosis in human ovarian cancer (7 November, 2013)

  Takemasa Tsuji, Kevin H Eng, Sacha Gnjatic, Junko Matsuzaki, Rachel Brightwell, Anthony Miliotto, Ryan Emerson, Cindy Desmarais, Erika Lindsley, Julie Rubinstein, Jianmin Wang, Song Liu, Harlan Robins, Kunle Odunsi
• CD40 expression in renal cell carcinoma correlates with tumor apoptosis, CD8 T cell frequency and patient survival (7 November, 2013)

  Jonathan M Weiss, Gregory Alvord, Octavio A Quinones, Jimmy K Stauffer, Robert H Wiltrout
• Study of circulating myeloid derived suppressor cells (MDSC) in patients with breast cancer undergoing neo-adjuvant chemotherapy; interim results (7 November, 2013)

  Robert Wesolowski, Joseph Markowitz, Bonnie Paul, Sarah Carothers, Mahmoud Abdel-Rasoul, William E Carson
• High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates (7 November, 2013) Free

  Michael K Wong, Gregory A Daniels, Howard L Kaufman, David F McDermott, Michael A Morse, Sandra Aung, James N Lowder
• STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors (7 November, 2013)

  Emmanuel T Akporiaye, Christopher Tucker, Todd Triplett, Kendra Garrison, Lihong Sun, Leona Ling, Andrew Weinberg
• Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP) (7 November, 2013)

  Paolo Antonio Ascierto, E Simeone, V Chiarion Sileni, P Queirolo, M Del Vecchio, L Di Guardo, M Guidoboni, P Marchetti, GC Antonini Cappellini, PF Ferrucci, F Cognetti, MG Bernengo, M Guida, R Marconcini, M Mandalà, C Cimminiello, G Rinaldi, M Aglietta, L Calabrò, M Maio
• Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival (7 November, 2013)

  Joseph R Broucek, Tasha Hughes, Erica J Huelsmann, Joseph L Poshepny, Carl E Ruby, Andrew Zloza, Howard L Kaufman
• Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment (7 November, 2013) Free

  Alessia Covre, Giulia Parisi, Hugues JMG Nicolay, Carolina Fazio, Ester Fonsatti, Elisabetta Fratta, Luca Sigalotti, Pietro Taverna, Gavin Choy, Mohammad Azab, Sandra Coral, Michele Maio
• Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model (7 November, 2013)

  Susan P Foy, Ryan B Rountree, Stefaine J Mandl, Joseph Cote, Tracy dela Cruz, Evan Gordon, Erica Trent, Alain Delcayre
• Histone deacetylase inhibitiors enhance sensitivity of murine sarcoma tumors to IL-13-PE immunotoxin-based cancer therapy by upregulating IL-13Rα2 expression in vitro and in vivo

  (7 November, 2013)

  Toshio Fujisawa, Hideyuki Nakashima, Bharat H Joshi, Raj K Puri
• Cyclophosphamide in combination with tumor lysate and TLR9 ligand regresses murine neuroblastoma (7 November, 2013)

  Jill Gershan, Kristen Barr, James Weber, Bryon Johnson
• Cyclophosphamide mechanism of action in preclinical tecemotide studies (7 November, 2013)

  Ken Hance, Robert Tighe, Jin Qi, William Hastings, Guozhong Qin, Bo Marelli, Hong Wang, Huakui Yu, Yanping Zhang, Xiaomei Xu, Wilson Guzman, Masie Wong, Giorgio Kradjian, Beatrice Brunkhorst, Helen Sabzevari, Yan Lan, Robert Hofmeister, Michael Wolf
• Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models (7 November, 2013) Free

  Li-Zhen He, Lawrence J Thomas, James Testa, Jeffrey Weidlick, Crystal Sisson, Russell Hammond, Laura Vitale, Henry Marsh, Tibor Keler
• Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4 (7 November, 2013)

  Rikke B Holmgaard, Dmitriy Zamarin, David H Munn, Jedd D Wolchok, James P Allison
• Targeted delivery of immunogenic antigen to the tumor microenvironment after irradiation facilitates tumor control (7 November, 2013)

  Tc Wu, Chien-Fu Hung
• MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction (7 November, 2013)

  Bryan A Irving, Jeanne Cheung, Yagai Yang, Marina Moskalenka, Marcin Kowanetz, Heather Maecker, Ira Mellman
• PreImplantation factor (PIF) potentiates static magnetic field (SMF) effect to decrease tumor burden (melanoma murine model) (7 November, 2013)

  Beatrix Kotlan, Janos F Laszlo, Jozsef Tovari, Miklos Kasler, Eytan Barnea
• Immunotargeting of tumor vasculature: preclinical development of novel antibody-based imaging and therapy against TEM1/CD248 (7 November, 2013)

  Chunsheng Li, Junying Wang, Jia Hu, Ann Marie Chacko, Aizhi Zhao, Chaitanya Divgi, Vladimir Muzykantov, George Coukos
• Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer (7 November, 2013)

  Stefanie N Linch, Melissa J Kasiewicz, William L Redmond
• Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells (7 November, 2013)

  Ravi A Madan, Hakim Frances, Caroline Jochems, Christopher R Heery, Geraldine C O’Sullivan, Harpreet Singh, Ira Surolia, Kwong Y Tsang, Ronald Gress, Jeffery Schlom, James L Gulley
• Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma (7 November, 2013)

  Igor Puzanov, Mohammed Milhem, Robert Andtbacka, David Minor, Omid Hamid, Ai Li, Ari VanderWalde, Howard Kaufman
• Combination chemoimmunotherapy with monthly cycles of 5-fluorouracil + interferon-alfa-2b in previously-treated advanced cancer (7 November, 2013)

  Walter Quan, Vivek Khemka, Laura S Martell, Marci J Pierog
• Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5- fluorouracil chemotherapy in the B16 melanoma model (7 November, 2013)

  Alexander Rakhmilevich, Xiaoyi Qu, Mildred Felder, Zulmarie Perez Horta, Paul Sondel
• Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity (7 November, 2013)

  William L Redmond, Stefanie N Linch, Melissa J Kasiewicz
• Cancer therapy by restoration of immune Notch (7 November, 2013)

  Anil Shanker, Duafalia F Dudimah, Roman V Uzhachenko, Asel K Biktasova, David P Carbone, Mikhail M Dikov
• IL-2 analogues: novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy (7 November, 2013)

  Geok Choo Sim, Elizabeth Grimm, ZhiMin Dai, Willem Overwijk, Patrick Hwu, Laszlo Radvanyi
• Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models (7 November, 2013) Free

  Micaël De Meyer, Isabelle Farine, Christelle Pichon, Ronald Rooke, Philippe Slos
• Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death (7 November, 2013)

  Andressa A Smith, James Hodge, Charlie Garnett, Benedetto Farsaci, Claudia Palena, Kwong-Yok Tsang, Soldano Ferrone, Sofia Gamiero
• Pre-operative intradermal administration of CpG-B ± GM-CSF in stage I-III melanoma patients arms the sentinel lymph node: evidence for reduced tumor spread (7 November, 2013) Free

  Mari F van den Hout, Bas D Koster, Rik J Scheper, Rieneke van de Ven, Berbel J Sluijter, Barbara G Molenkamp, Alfons J van den Eertwegh, Paul A van Leeuwen, Petrousjka M van den Tol, Tanja D de Gruijl
• MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells (7 November, 2013)

  Laura J Vella, Anupama Pasam, Nektaria Dimopoulos, Miles Andrews, Anne-Laure Puaux, Jamila Louahed, Ashley Knights, Weisan Chan, Katherine Woods, Jonathan Cebon
• Magnitude of CD8 cell reactivity with a peptide pool is comparable to the sum of responses by individual peptides (7 November, 2013)

  Tameem Ansari, Wenji Zhang, Ioana Moldovan, OLeg Targoni, Ramu A Subbramanian, Paul V Lehmann
• User vs. software-dependent variability of ELISPOT counts obtained from ten different laboratories (7 November, 2013)

  Tameem Ansari, Alexey Karulin, Paul V Lehmann, Srividya Sundararaman
• Precision analysis of a whole blood T cell subset immunophenotyping assay (7 November, 2013) Free

  Minjun Apodaca, Stephen C De Rosa, Leonard A D'Amico, Bryan J Kennedy, Mary L Disis, Chihiro Morishima
• Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine (7 November, 2013)

  Benedetto Farsaci, Caroline Jochems, Italia Grenga, Renee N Donahue, James L Gulley, Christopher R Heery, Ravi A Madan, Jeffrey Schlom
• ELISPOTs produced by CD8 and CD4 cells follow log normal size distribution (7 November, 2013)

  Jaya Ghosh, Kinga Karacsony, Wenji Zhang, Oleg Targoni, Ioana Moldovan, Paul V Lehmann, Alexey Y Karulin
• Mobilization permits reliable ELISPOT detection of long-term memory T cells secreting IFN-γ, IL-4, IL-5, and IL-17 without in vitro expansion (7 November, 2013)

  Jaya Ghosh, Alyssa Mills, Marie Wunsch, Edith Karacsony, Wenji Zhang, Jodi Hanson, Paul V Lehmann
• Bystander memory CD8 T cell proliferation after anti-CD40/IL-2 treatment is independent of CD4 T cells (7 November, 2013)

  Steven K Grossenbacher, Arta M Monjazeb, Julia Tietze, Gail D Sckisel, Annie Mirsoian, Hui-Hua Hsiao, Brent Koehn, Danice Wilkins, Bruce R Blazer, William J Murphy
• Induction of antigen spread after sipuleucel-T treatment and its association with improved clinical outcome (7 November, 2013)

  Debraj GuhaThakurta, Li-Qun Fan, Tuyen Vu, Nadeem A Sheikh, James B Trager
• Ten-color, whole blood flow cytometric analysis of human myeloid subsets; implications for immune monitoring in cancer patients (7 November, 2013)

  Michael P Gustafson, Yi Lin, Mary L Maas, Dennis A Gastineau, Allan B Dietz
• A novel biomarker assay for cancer immunotherapy development based on myeloid derived supressor cells (MDSCs) (7 November, 2013)

  Henry Hepburne-Scott
• Immunologic hierarchy and promiscuity of melanoma helper peptides (7 November, 2013)

  Yinin Hu, Gina R Petroni, Walter C Olson, Andrea Czarkowski, Mark Smolkin, William W Grosh, Patrice K Rehm, Cheryl F Murphy, Elizabeth J Coleman
• Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease (7 November, 2013)

  Tasha Hughes, Gail Iodice, Sanjib Basu, Steven Bines, Howard Kaufman
• Immunological and polyfunctional T cell profiling following therapy with DPX-Survivac as a predictive tool of vaccine efficacy (7 November, 2013)

  Mohan Karkada, Mieko Ogura, Vivian Tovar, Masato Mitsuhashi, Neil Berinstein, Marc Mansour
• Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study (7 November, 2013)

  Cristina Maccalli, Hugues Nicolay, Filippo Capocefalo, Ester Fonsatti, Carla Chiarucci, Ornella Cutaia, Diana Giannarelli, Giorgio Parmiani, Anna Maria Di Giacomo, Michele Maio
• Peptide-induced mRNAs in whole blood ex vivo as a unique assay for peptide-specific T cell immunity (7 November, 2013)

  Masato Mitsuhashi, Jane B Trepel, Min-Jung Lee, Sunmin Lee, Masaki Terabe, Jay A Berzofsky, Lauren V Wood
• Heterodimeric IL-15 regulates the differentiation and survival of different populations of memory T cells and the balance of effector and regulatory cells (7 November, 2013)

  George N Pavlakis, Cristina Bergamaschi, Jinyao Li, Antonio Valentin, Stephanie Chen, Sinnie S Ng, Rachel E Kelly Beach, Jenifer Bear, Margherita Rosati, Candido Alicea, Raymond Sowder, Elena Chertova, Barbara K Felber
• Does the number of apoptotic cells in PBMC reveal the extent of impairment in T cell functionality? (7 November, 2013)

  Srividya Sundararaman, Marie Wunsch, Richard Caspell, Paul V Lehmann
• How frequently are predicted peptides actually recognized by CD8 cells? (7 November, 2013)

  Srividya Sundararaman, Ioana Moldovan, Oleg Targoni, Wenji Zhang, Paul V Lehmann
• ImmunTraCkeR^® as a reliable TCR repertoire profiling tool to understand immune response and to explore immunotherapy biomarkers

  (7 November, 2013)

  Isabelle Tanneau, Audrey Nondé, Anaïs Courtier, Gilles Parmentier, Marlène Noël, Audrey Grivès, Solène Perez, Nadia Plantier, Jean-François Mouret, Orchidée Filipe-Santos, Manuarii Manuel
• Novel strategy to monitor apparent tumor-specific T cells in patients with cancer (7 November, 2013)

  Rieneke van de Ven, Traci L Hilton, Christopher J Dubay, Sachin Puri, Hong-Ming Hu, Rom S Leidner, R Bryan Bell, Walter J Urba, Brendan D Curti, Sandra Aung, Bernard A Fox
• Colorectal cancer patients show decrease in cellular immunity and enhanced plasma level of transforming growth factor – beta and vascular endothelial growth factor (VEGF) (7 November, 2013)

  Eva Zavadova, Vocka Michal, Konopasek Bohuslav, Terezie Fučíkova, Blanka Rihova, Luboš Petruzelka
• The abscopal effect of local radiotherapy is induced by TGFβ blockade (7 November, 2013)

  Julie Diamond, Claire Vanpouille-Box, Mary Helen Barcellos-Hoff, Silvia C Formenti, Sandra Demaria
• Immune consequences of CT-guided radiation therapy of mouse mammary tumors (7 November, 2013)

  Michael J Gough, Kristina H Young, Benjamin L Cottam, Talicia Savage, Jason R Baird, David Friedman, Marka R Crittenden
• Dendritic cells cross-presenting tumor-derived antigens are eliminated by invariant natural killer T (iNKT) cells, impairing development of anti-tumor immunity to a mouse carcinoma (7 November, 2013)

  Karsten A Pilones, Joseph Aryankalayil, Silvia Formenti, Sandra Demaria
• Stereotactic body radiation therapy and CTLA-4 blockade as a novel therapy for advanced melanoma (7 November, 2013)

  Christina Twyman, Andrew Rech, Ramesh Rengan, Robert Vonderheide, Andy Minn
• Activin A is upregulated by radiation in breast cancer cells and promotes conversion of CD4 T cells into regulatory T cells (7 November, 2013)

  Claire Vanpouille-Box, Julie Diamond, Silvia Fomenti, Sandra Demaria
• Improved efficacy of radiation in combination with TGFβ inhibition in a colorectal cancer mouse model (7 November, 2013)

  Kristina H Young, Benjamin Cottam, Talicia Savage, Jason Baird, David Friedman, Emmanuel Akporiaye, Michael J Gough, Marka Crittenden
• Induction of an acute vitamin A-deficient state following total body irradiation impairs anti-tumor immunity by altering the homeostasis of pre-cDC derived dendritic cells (7 November, 2013)

  Christopher A Klebanoff, Sean Spencer, Rahu Roychoudhuri, Yun Ji, Madhu Sukumar, Pawel Muranski, Joseph L Napoli, Luca Gattinoni, Yasmine Belkaid, Nicholas P Restifo
• The impact of metabolic stress on anti-tumor immunity in laboratory mice (7 November, 2013)

  Kathleen M Kokolus, Maegan L Capitano, Jason W Eng, Bonnie L Hylander, Christopher J Gordon, Scott I Abrams, Elizabeth A Repasky
• NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity (7 November, 2013)

  Guanqiao Li, Xiaoyan Liang, Michael Lotze
• Telomere length in relation to incident chronic stress in the Bangladeshi-American: the experience from the Massachusetts United States of America (7 November, 2013)

  Md Ariful Haque Mollik
• Interferon (IFNγ) induces cell cycle arrest in RCC cell lines (7 November, 2013)

  David J Tate, John R Patterson, Beatriz Finkel-Jimenez, Arnold H Zea
• Antitumor efficacy of D2C7-(scdsFv)-PE38KDEL, a novel immunotoxin targeting EGFRwt and EGFRvIII, by convection-enhanced delivery in orthotopic brain tumor mouse models (7 November, 2013)

  Xuhui Bao, Vidyalakshmi Chandramohan, Stephen T Keir, Charles N Pegram, Roger E McLendon, Chien-Tsun Kuan, Ira H Pastan, Darell D Bigner
• A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors (7 November, 2013)

  Howard Burris, Stephen Ansell, John Neumanitis, Geoffrey Weiss, Branimir Sikic, Donald Northfelt, Lana Pilja, Thomas Davis, Michael Yellin, Tibor Keler, Timothy Bullock
• Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles (7 November, 2013)

  Catja Freiburghaus, Sissela Broos, Linda C Sandin, Thomas H Tötterman, Takami Akagi, Mitsuru Akashi, Carl Borrebaeck, Peter Ellmark, Malin Lindstedt
• Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients (7 November, 2013) Free

  Michael Morse, Elizabeth Gabitzsch, Joseph P Balint, Younong Xu, HK Lyerly, Frank Jones
• Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes (7 November, 2013)

  Simon S Jensen, Pia T Johansen, Daniel Zucker, Jonas Henriksen, Thomas Andresen, Alcide Barberis, Roberto Maj, Houman Pourhassan, Jeanette Wern, Monika Gad
• Whole-body heat treatment stimulates antigen-specific T cell responses in human system (7 November, 2013)

  Yasunobu Kobayashi, Yusuke Ito, Mayuko Sakai, Masanori Matsushita, Kenichiro Imai, Koichi Shimizu, Atsushi Aruga, Keishi Tanigawa
• A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma (7 November, 2013)

  Lee Krug, Alessandra di Pietro, Rajesh Narwal, Paul Robbins, Dongyue Fu, Aiman Shalabi, Ramy Ibrahim, Luana Calabro, Hedy Kindler
• Targeted tumor therapy: turning the genome on its head (7 November, 2013)

  Matthew M Lawler, Ian S Dunn, Estelle E Newton, Lenora B Rose, James T Kurnick
• Combination of trichosanthes cucumerina L. compounds: an analysis for novel effects of anticancer cell activites as probes for pharmacological studies (7 November, 2013)

  Md Ariful Haque Mollik
• Identification of novel immune checkpoints as targets for cancer immunotherapy (7 November, 2013)

  Galit Rotman, Ofer Levy, Amir Toporik, Gady Cojocaru, Liat Dassa, Iris Hecht, Ilan Vaknin, Anat Oren, Zohar Tiran, Nora Tarcic, Sergey Nemzer, Tania Pergam, Amit Novik, Shirley Sameah-Greenwald, Joseph R Podojil, Stephen D Miller, Judith Leitner, Peter Steinberger, Eyal Neria, Zurit Levine
• Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate (7 November, 2013)

  Martin Skarzynski, Bérengère Vire, Joshua D Thomas, Christopher G Nelson, Alexandre David, Georg Aue, Terrence R Burke, Christoph Rader, Adrian Wiestner
• Interleukin-15 (IL-15) and IL-15 receptor alpha fusion protein enhances antitumor activity of myxoma virus (7 November, 2013)

  Vesna Tosic, Diana L Thomas, David M Kranz, Jia Liu, Grant McFadden, Amy L MacNeill, Edward J Roy
• Intratumoral immunotherapy with the TLR7/8 agonist 3M-052 (7 November, 2013)

  DV Smirnov, G Zhao, JM Beaurline, KE Johnson, JT Capecchi, LI Harrison, MA Tomai, JM Elvecrog, DM Klinman, JP Vasilakos
• What transposable elements are differentially translated in lung cancer? (7 November, 2013)

  Wan R Yang, Eric W Mills, Nemanja Rodic, Nicholas T Ingolia, Jef D Boeke, Hyam I Levitsky, Kathleen H Burns
• Tumor associated MUC1 carried by microvesicles is cross-processed by dendritic cells generating CD8+ T cell response (7 November, 2013)

  Ilaria G Zizzari, Federico Battisti, Chiara Napoletano, Hassan Rahimi, Salvatore Caponnetto, Paola Martufi, Stefania Salvati, Morena Antonilli, Francesca Belleudi, Marianna Nuti, Aurelia Rughetti
• NGS technology applied to melanoma cell lines (7 November, 2013)

  Valeria De Giorgi, Zhi Xie, Jinguo Chen, Rongye Shi, Huizhi Zhou, Hui Liu, John Wunderlich, Michele Sommariva, Sara Tomei, Maria Libera Ascierto, Davide Bedognetti, Ena Wang, Francesco M Marincola
• Expression profiling of suppressive monocytes (CD14+HLA-DRlow/neg) in cancer patients (7 November, 2013)

  Stefan F Cordes, Michael P Gustafson, Zhe Zhang, Peggy A Bulur, Dennis A Gastineau, Yi Lin, Allan B Dietz
• Tumor-associated T cell receptor repertoires in low- and high-grade gliomas (7 November, 2013)

  Jennifer S Sims, Boris Grinshpun, Benjamin I Amendolara, Yufeng Shen, Peter D Canoll, Peter A Sims, Jeffrey N Bruce
• The impact of cellular senescence and DNA damage on colorectal tumour progression (7 November, 2013)

  Helen K Angell, Marie Tosolini, Bernhard Mlecnik, Gabriela Bindea, Tessa Fredriksen, Lucie Lafontaine, Maximilian Waldner, Franck Pagès, Viia Valge-Archer, Jérôme Galon
• The role of surgery following incomplete response to high-dose IL-2 (HD IL-2) (7 November, 2013)

  Tasha Hughes, Gail Iodice, Sanjib Basu, Steven Bines, Howard Kaufman
• Development and stability of Th17 cells in ovarian cancer requires nitric oxide and endogenous NOS2 activity in cancer-associated CD4+ T cells (7 November, 2013)

  Natasa Obermajer, Jeffrey L Wong, Robert P Edwards, Kong Chen, Melanie Scott, Shabaana Khader, Jay K Kolls, Kunle Odunsi, Timothy R Billiar, Pawel Kalinski
• Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer (7 November, 2013)

  Jennifer L Bishop, Barinder Sangha, Martin Gleave, Amina Zoubeidi
• Calreticulin mediates immune recognition of acute myeloid leukemia cells in vivo (7 November, 2013)

  Xiufen Chen, Dominick Fosco, Douglas E Kline, Justin Kline
• Clinical outcomes of Interleukin-2 therapy in advanced cancer: meta-analysis of over 62 trials (7 November, 2013)

  Brendon J Coventry, Martin L Ashdown, Richard Bright
• Mathematical modeling of immune kinetics in advanced cancer through meta-analyses of complete response rates: immune synchronisation emerges as the likely key determinant of clinical response (7 November, 2013)

  Martin L Ashdown, Brendon J Coventry, Derek Abbott
• Targeting of phosphatidylserine by monoclonal antibodies reverses an immunosuppressive checkpoint inducing innate and specific anti-tumor responses (7 November, 2013) Free

  Jian Gong, Rich Archer, Van Nguyen, Jeff Hutchins, Bruce Freimark
• High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack (7 November, 2013)

  Duane H Hamilton, Bruce Huang, Romaine I Fernando, Kwong-Yok Tsang, Claudia Palena
• Role of the Wnt-β-catenin signaling pathway in melanoma-mediated dendritic cell tolerization (7 November, 2013) Free

  Alisha Holtzhausen, Kathy Evans, Brent A Hanks
• Phosphatidylserine-targeting antibody induces M1 macrophage polarization, promotes myeloid derived suppressor cell differentiation and boosts tumor-specific immunity (7 November, 2013)

  Xianming Huang, Yi Yin, Dan Ye, Rolf Brekken, Philip Thorpe
• Vascular normalization: a strategy to recondition the tumor immune microenvironment (7 November, 2013)

  Yuhui Huang, Jianping Yuan, Elda Righi, Dan G Duda, Dai Fukumura, Mark C Poznansky, Rakesh K Jain
• PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses (7 November, 2013)

  Erica Huelsmann, Joseph Broucek, Andrew Lacek, Eugene Lusciks, Johnson Saba, Arman Nabatiyan, Andrew Zloza
• Siglec-7/-9 ligands shield tumor cells from NK cell attack (7 November, 2013)

  Camilla Jandus, Kayluz Frias Boligan, Obinna Chijioke, He Liu, Meike Dahlhaus, Thomas Démoulins, Christoph Schneider, Marc Wehrli, Robert E Hunger, Gabriela M Baerlocher, Hans-Uwe Simon, Pedro Romero, Christian Münz, Stephan von Gunten
• CD8α+ dendritic cells dictate immune responses against murine AML (7 November, 2013)

  Douglas E Kline, Dominick Fosco, Xiufen Chen, Justin Kline
• Proangiogenic neutrophilic-myeloid-derived suppressor cells emerge via two parallel pathways in renal cell carcinoma and melanoma (7 November, 2013)

  Jennifer Ko, Patricia Rayman, Dana Obery, Daniel Lindner, Ernest Borden, James Finke
• New strategy to reveal the black seeds of melanomas (cancer stem cells) with their vulnerable characteristics at cellular and molecular levels (7 November, 2013)

  Beatrix Kotlan, Gabriella Liszkay, Gyorgy Naszados, Zoltan Dolescall, Laszlo Toth, Laszlo Gobor, Istvan N Vamosy, Andras Szollar, Szabolcs Horvath, Klara Eles, Orsolya Csuka, Miklos Kasler, Maria Godeny, Francesco M Marincola
• Immune checkpoints in MSI and CSI colorectal cancers and their translational implications (7 November, 2013)

  Nicolás J Llosa, Franck Housseau, Elizabeth Wick, Lizzy Hechenbleikner, Michael Cruise, Robert Anders, Cynthia Sears, Drew Pardoll
• Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions (7 November, 2013)

  Danielle M Lussier, Lizbeth M Nieves, Megan S McAfee, Trung P Hyunh, Susan A Holechek, Pooja Hingorani, Joseph N Blattman
• Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients (7 November, 2013)

  Thomas A Mace, Jason Pitaressi, Reena Shakya, Wendy Frankel, Tim Eubank, Tanios Bekaii-Saab, Mark Bloomston, Mitch Phelps, Thomas Ludwig, Michael Ostrowski, Gregory B Lesinski
• Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity (7 November, 2013)

  Shruti Malu, Rina Mbofung, Jahan Khalili, Nikunj Satani, Marie-Andrée Forget, Cara Haymaker, Florian Muller, Chantale Bernatchez, Laszlo Radvanyi, Patrick Hwu
• Tumor derived exosome induction of the CD3+CD8+ T cell tolerogenic phenotype (7 November, 2013)

  Brian Maybruck, Brian Gastman
• Hepatic myeloid-derived suppressor cells in tumor bearing mice exacerbate hepatitis and transform into pro-inflammatory myeloid cells (7 November, 2013)

  Jose Medina-Echeverz, Tamar Kapanadze, Chi Ma, Austin Duffy, Jaba Gamrekelashvili, Veena Kapoor, Jonathan M Weiss, Robert H Wiltrout, Jay Berzofsky, Masaki Terabe, Michael P Manns, Francesco M Marincola, Ena Wang, Firouzeh Korangy, Tim F Greten
• Expression of neuropilin-1 on in vivo induced regulatory T cells (7 November, 2013)

  Christopher J Nirschl, Christina Ceccato, Angela Alme, Brian Francica, Charles G Drake
• Immunosuppression through HNF-1β signaling in human ovarian clear cell cancer (7 November, 2013)

  Hiroshi Nishio, Juri Sugiyama, Tomonori Yaguchi, Daisuke Aoki, Yutaka Kawakami
• Understanding and overcoming the immunosuppressive effects of glioma induced immunosuppression (7 November, 2013) Free

  Christopher Moertel, Junzhe Xi, Michael R Olin
• Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells (7 November, 2013)

  Kyle K Payne, Christine K Zoon, Wen Wan, Khin Marlar, Rebecca C Keim, Mehrab Nasiri Kenari, Latif Kazim, Harry D Bear, Masoud H Manjili
• Tumor-induced suppressive CD8+ T cells: implications for cancer immunotherapy (7 November, 2013)

  Lukas W Pfannenstiel, Brian R Gastman
• Indoleamine 2,3-dioxygenase-1 (IDO1) expression by childhood acute myeloid leukemias inhibits T-cell production of IFN-γ and confers an unfavorable prognosis (7 November, 2013)

  Sergio Rutella, Valentina Folgiero, Perla Filippini, Valentina Bertaina, Riccardo Masetti, Marco Zecca, Giuseppina Li Pira, Giovanni F Torelli, Anna Maria Testi, Alice Bertaina, Andrea Pession, Franco Locatelli
• Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment (7 November, 2013) Free

  Sadna Budhu, David Schaer, Yongbiao Li, Alan Houghton, Samuel Silverstein, Taha Merghoub, Jedd Wolchok
• HLA-G-specific microRNAs a novel approach for targeting tumors (7 November, 2013) Free

  Simon Jasinski-Bergner, Arndt Hartmann, Verena Spath, Stefan Huettelmaier, Juliane Braun, Juergen Bukur, Barbara Seliger
• STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients (7 November, 2013)

  Raghvendra M Srivastava, Hyun-bae Jie, Soldano Ferrone, Robert L Ferris
• Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells (7 November, 2013)

  Sandrine Valsesia-Wittmann, Beatrice Clemenceau, Anne-Catherine Jallas, Jean-Yves Blay, Aurelien Marabelle, Christophe Caux, Henri Vie
• miR-138 exerts anti-glioma efficacy by targeting immune checkpoints (7 November, 2013)

  Jun Wei, Edjah Nduom, Ling-Yuan Kong, Fei Wang, Shuo Xu, Konrad Gabrusiewicz, Ali Alum, Greg Fuller, George Calin, Amy B Heimberger
• Immunotherapy targeting esophageal cancer stem cells (7 November, 2013) Free

  Dongli Yue, Hongzheng Ren, Lan Huang, Yi Zhang
• Tumor monocyte cross talk promotes lymphoma cell resistance to chemotherapy (7 November, 2013) Free

  Zhe (Jenny) Zhang, Peggy A Bulur, Michael P Gustafson, Dennis A Gastineau, Allan B Dietz, Yi Lin
• Melanoma-associated B cells are distinct from peripheral blood-derived B cells, and may serve as a source of tumor-targeting antibodies (7 November, 2013)

  Daniel Abate-Daga, Theresa A Alexander, Evgeny Arons, Mitchell Ho, Paul F Robbins, Steven A Rosenberg, Richard A Morgan
• Prognostically relevant natural killer cell-mediated immunoediting in acute myeloid leukemia (7 November, 2013)

  Christopher J Chan, Daniel M Andrews, Mark J Smyth, Paul J Neeson, David S Ritchie
• Dynamic regulation of macrophage polarization via coupled multicellular networks (7 November, 2013)

  Yishan Chuang, Joshua N Leonard
• Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells (7 November, 2013)

  Renee N Donahue, Italia Grenga, Jeffrey Schlom, Benedetto Farsaci
• Cross talks between the immune and lymphatic endothelial cells regulate inflammatory lymph node lymphangiogenesis: defining a new therapeutic approach (7 November, 2013)

  Sonia Elhadad
• A role for immunotherapy: preventing macrophage anergy in the tumour environment (7 November, 2013)

  Androulla Elia, James Mapes, Thomas Knorpp, Manfred Schmolz, Eric Garcia, Thorsten Hagemann, Laura Rosa Brunet
• Uncovering a connection between physiological stress and therapeutic resistance in tumor cells (7 November, 2013) Free

  Jason W Eng, Chelsey Reed, Kathleen M Kokolus, Rose Pitoniak, Bonnie L Hylander, Elizabeth A Repasky
• Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas (7 November, 2013)

  Romaine I Fernando, Duane H Hamilton, Bruce Huang, Claudia Palena
• Bone marrow-derived progenitor cells develop into myeloid-derived suppressor cells at metastatic sites (7 November, 2013)

  Amber Giles, Yorleny Vicioso, Miki Kasai, Steven Highfill, Arnulfo Mendoza, Rosandra Kaplan
• Trp53 inactivation in the tumor microenvironment promotes tumor progression by enhancing pro-inflammatory tumor stromal populations (7 November, 2013) Free

  Gang Guo, Luis Marrero, Augusto Ochoa, Yan Cui
• TIM-3⁺ T cells are not exhausted but activated cells in the tumor microenvironment

  (7 November, 2013)

  Hyun-Bae Jie, Jing Li, Raghvendra Srivastava, Robert L Ferris
• Synergistic induction of cancer-related immunosuppression by β2-adrenergic stress mediators and P38MAPK inflammatory pathway (7 November, 2013)

  Ravikumar Muthuswamy, Frank Jenkins, Dana Bovbjerg, Pawel Kalinski
• Neutrophils from renal cell carcinoma patients show increased expression of immunosuppressive and angiogenic gene profile (7 November, 2013)

  Dana R Obery, Patricia A Rayman, Yu Yang, Jennifer S Ko, James H Finke
• Independent mechanisms of T cell-suppression by subpopulations of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts (7 November, 2013) Free

  Patrick L Raber, Paul Thevenot, Rosa Sierra, Dorota Wyczechowska, Maria E Ramirez, Augusto Ochoa, Cruz Velasco, Paulo C Rodriguez
• Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties (7 November, 2013)

  Jason Williams, Yan Zheng, Thomas Gajewski
• Dendritic cells inhibit myeloid-derived suppressor cells infiltration and function in mouse B16 melanoma microenvironment (7 November, 2013)

  Siyuan Xia, Jun Wei, Jingya Wang, Liqing Zhao, Zhinan Yin
• New equipment optimized for emulsified vaccine prepation in the hospital (7 November, 2013)

  Stephane Ascarateil, Marie Eve Koziol
• Intradermal influenza vaccination in complete remission cancer patients: molecular insights (7 November, 2013)

  Davide Bedognetti, Maria Libera Ascierto, Marimo Sato-Matsushita, Elena Gugiatti, Carlotta Massucco, Simonetta Zupo, Antonio Di Meglio, Chiara Dellepiane, Mario Roberto Sertoli, Omar Racchi, Enrico Balleari, Valeria De Giorgi, Michele Sommariva, Paolo Durando, Manlio Ferrarini, Roberto Cacciani, Nicoletta Provinciali, Rocco Iudici, Cristiano Alicino, Ena Wang, Filippo Ansaldi, Francesco M Marincola, Andrea De Maria
• Talilmogene Iaherparepvec generates systemic T-cell-mediated anti-tumor immunity (7 November, 2013) Free

  Julia Piasecki, Le Tiep, Jean Zhou, Courtney Beers
• Calcium ionophore pre-treatment induces type-1 polarized DCs with enhanced T cell stimulatory function and IL-12 production (7 November, 2013)

  Erik Berk, Shuwen Xu, Min Xu, Julia Terhune, Brian Czerniecki
• Preliminary results for the phase 1 trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients (7 November, 2013) Free

  John S Berry, Erika J Schneble, Alfred F Trappey, Timothy J Vreeland, Guy T Clifton, Diane F Hale, Alan K Sears, Sathibalan Ponniah, Elizabeth A Mittendorf, George E Peoples
• Design, development and production of nano-particle-based anticancer vaccine targeting human aspartyl (asparaginyl) β-hydroxylase (HAAH) (7 November, 2013) Free

  Biswajit Biswas, Solomon Stewart, Kanam Malhotra, Michael Lebowitz, Steven Fuller, Carl Merril, Hossein Ghanbari
• Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT) (7 November, 2013)

  Benjamin Boyerinas, Jo A Tucker, Diane J Poole, Caroline Jochéms, Claudia Palena, Jeffrey Schlom, Kwong Y Tsang
• Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors (7 November, 2013)

  Dirk G Brockstedt, Dung T Le, Raffit Hassan, Aimee Murphy, John Grous, Thomas W Dubensky, Elizabeth M Jaffee
• B lymphocyte mediated antigen presentation of plasmid DNA (7 November, 2013)

  Viswa Teja Colluru, Douglas G McNeel
• Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study (7 November, 2013) Free

  Tanja de Gruijl, Saskia Santegoeds, Sandra van Wetering, Satwinder Kaur Singh, Anthony Hall, Arjan A van de Loosdrecht, Ada Kruisbeek
• Development of a unique anti-AML immune therapy consisting of cord blood HSCT and cord blood stem cell-derived dendritic cell (CB-DC) vaccination (7 November, 2013)

  Colin de Haar, Maud Plantinga, Nina Blokland, Lotte Spel, Marianne Boes, Stefan Nierkens, Jaap Jan Boelens
• Multi-functional cytotoxic T cell expansion correlates with overall survival after administration of autologous dendritic cell immunotherapy in renal cell cancer patients (7 November, 2013)

  M DeBenedette, I Jurisica, A Gamble, W Lewis, E Wansley, I Tcherepanova, C Nicolette
• High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine (7 November, 2013)

  Robert O Dillman, Carol DePriest, Stephanie E McClure
• A multi-epitope melanoma helper peptide vaccine durably increases Th1 cytokine production by responding lymphocytes (7 November, 2013)

  Patrick M Dillon, Walter C Olson, Andrea Czarkowski, Gina R Petroni, Mark Smolkin, William W Grosh, Kimberly A Chianese-Bullock, Donna H Deacon, Craig L Slingluff
• Immunogenicity of a lambda phage-based anti-cancer vaccine targeting HAAH (7 November, 2013) Free

  Steven Fuller, Solomon Stewart, Michael Lebowitz, Kanam Malhotra, Mark Semenuk, Biswajit Biswas, Hossein Ghanbari
• Optimizing the cryopreservation of murine splenocytes for improved antigen-specific T cell function in ELISPOT (7 November, 2013)

  Ekram Gad, Lauren Rastetter, Dan Herendeen, Benjamin Curtis, Meredith Slota, Marlese Koehniein, Nora Disis
• Safety and efficacy of a genetic vaccine targeting Telomerase plus chemotherapy for the therapy of canine B-cell lymphoma (7 November, 2013) Free

  Alessandra Gavazza, George Lubas, Arthur Fridman, Daniela Peruzzi, Joseph A Impellizeri, Laura Luberto, Emanuele Marra, Giuseppe Roscilli, Gennaro Ciliberto, Luigi Aurisicchio
• Study of autologous dendritic cell therapy targeting Mucin 1 as a treatment for the maintenance of ovarian cancer patients in remission (7 November, 2013)

  J Goh, J Mason, J Chan, M Moradi, J Berek, B Beningno, L Mileshkin, F Recio, N Tchabo, E Rossi, P Eisenberg, P Rose, P Mitchell, J Young, M Matos, A Secord, M Davy, S Gargosky, H Gray
• Dipeptidyl peptidase 3 and thimet oligopeptidase 1 knockdown support tumor-specific immune responses to whole cell cancer vaccines and tumor cell death in vivo (7 November, 2013) Free

  Jaba Gamrekelashvili, Miaojun Han, Tamar Kapanadze, Josef Wissing, Chi Ma, Lothar Jaensch, Todd Armstrong, Liz Jaffee, Ayla White, Deborah Citrin, Firouzeh Korangy, Tim Greten
• Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer (7 November, 2013) Free

  Androulla Elia, Louise Lincoln, Laura Rosa Brunet, Thorsten Hagemann
• Epitope-optimization creates highly immunogenic alpha fetoprotein antigen to break immune tolerance and potently activates CD8 T cells to prevents autochthonous hepatocellular carcinoma (7 November, 2013) Free

  Yuan Hong, Yibing Peng, Sheng Z Guo, Junfeng Pang, Jose Guevara-patino, David H Munn, Nahid Mivechi, David Bartlett, Yukai He
• Chemical carcinogens used to induce spontaneous tumors may suppress tumor specific T-cell immunity (7 November, 2013)

  Dan Herendeen, Ekram Gad, Lauren Rastetter, Dominick Auci, Ben Curtis, Marlese Koehnlein, Mary L Disis
• Identification and characterization of agonist epitopes of the MUC1-C oncoprotein (7 November, 2013)

  Caroline Jochems, Jo A Tucker, Matteo Vergati, Benjamin Boyerinas, James L Gulley, Jeffrey Schlom, Kwong-Yok Tsang
• A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses (7 November, 2013)

  Karl-Josef Kallen, Ulrike Gnad-Vogt, Birgit Scheel, Gerd Rippin, Arnulf Stenzl
• Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer (7 November, 2013)

  Lana E Kandalaft, Cheryl Chiang, Emese Zsiros, Janos Tanyi, Daniel Powell, Rosemarie Mick, George Coukos
• Novel alphavirus-based vaccine induces strong immune responses against prostate-specific antigen (PSA) and mediates tumor cell elimination in a mouse model of prostate cancer (7 November, 2013)

  Vladimir Ryabov, Peter Pushko, Irina Tretyakova, Rikka Saito, Richard B Alexander, Elena N Klyushnenkova
• Depletion of platelets enhances therapeutic antitumor effects generated by therapeutic DNA vaccine (7 November, 2013)

  Sung Yong Lee, Tae Heung Kang, Jayne Knoff, Chien-Fu Hung, Tc Wu, Kyung Ho Kang, Jae Jeong Shim
• Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies (7 November, 2013)

  Anne Letsch, Carmen Scheibenbogen, Antonia Busse, Sebastian Ochsenreither, Igor Wolfgang Blau, Claudia Baldus, Eckhard Thiel, Ulrich Keilholz
• Development of mutome-specific personalized vaccines for pancreatic cancer (7 November, 2013)

  Eric Lutz, Heather Kinkead, Allison Yager, Todd Armstrong, Peter Lauer, Dirk Brockstedt, Thomas Dubensky, Elizabeth Jaffee
• Ganglioside containing nano-proteoliposome dampens myeloid-derived suppressor cells function and ability to cross-present tumor antigens: a new approach to recover CTL function on tumor bearing individuals (7 November, 2013) Free

  Audry Fernández, Liliana Oliver, Maura Rábade-Chediak, Rydell Alvarez, Arletty Hernández, Leslie Pérez, Luis E Fernández, Circe Mesa
• Targeting hematologic malignancies with oncolytic vaccinia virus constructs (7 November, 2013) Free

  Nanhai Chen, Mehmet Kilinc, Qian Zhang, Jason Aguilar, Desislava Tsoneva, Maysam Pessian, Boris Minev, Aladar Szalay
• Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer (7 November, 2013)

  Chiara Napoletano, Valeria Visconti, Morena Antonilli, Ilaria G Zizzari, Hassan Rahimi, Federico Battisti, Salvatore Caponnetto, Giacomo Barchiesi, Aurelia Rughetti, Filippo Bellati, Pierluigi Benedetti-Panici, Marianna Nuti
• Promise and challenges of peptide-poly: ICLC vaccines for adult and pediatric gliomas (7 November, 2013)

  Hideho Okada, Lisa H Butterfield, Ronald L Hamilton, Andres M Salazar, Douglas M Potter, Frank S Lieberman, Ian F Pollack
• Antibody response to melanoma helper-peptide vaccine correlates with survival (7 November, 2013)

  Walter C Olson, Caroline M Reed, Craig L Slingluff
• Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target (7 November, 2013)

  Claudia Palena, Romaine I Fernando, Duane H Hamilton, Bruce Huang, Jeffrey Schlom
• ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer (7 November, 2013)

  Robert G Petit, Partha Basu
• T cell stimulation by dendritic cell-tumor cell hybrids is enhanced in the presence of free dendritic cells (7 November, 2013)

  Mariana P Pinho, Patricia C Bergami-Santos, José Alexandre M Barbuto
• Epitope optimization of a DNA vaccine targeting SSX-2 leads to PD-1 upregulation on antigen-specific CD8 T cells and PD-L1 upregulation on tumor cells (7 November, 2013)

  Brian Rekoske, Heath A Smith, Douglas G McNeel
• The impact of age on a mitoxantrone-based tumor vaccine (7 November, 2013) Free

  Keven Stonewall, Cecilia Quintero, Andrew Zloza, Howard Kaufman, Carl Ruby
• EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer (7 November, 2013)

  Tetsuro Sasada, Teppei Yamada, Koichi Azuma, Satoko Matsueda, Kyogo Itoh
• Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients (7 November, 2013)

  Erika J Schneble, John S Berry, Alfred F Trappey, Timothy J Vreeland, Diane F Hale, Alan K Sears, Guy T Clifton, Sathibalan Ponniah, Nathan M Shumway, Elizabeth A Mittendorf, George E Peoples
• Vaccination with pre-diagnostic tumor antigens but not established tumor antigens inhibits spontaneous tumorigenesis in TgMMTV-neu mice (7 November, 2013)

  Sasha E Stanton, Jianning Mao, John Ladd, Lauren Rastedder, Ekram Gad, Samir Hanash, Hailing Lu, Mary L Disis
• DCVax^®- DIRECT: autologous activated dendritic cells for image guided intra-tumoral vaccination in patients with solid tumors - a phase I/II clinical trial in progress

  (7 November, 2013) Free

  Vivek Subbiah, Ravi Murthy, Chitra Hosing, Indresh Kaur, Gerald Falchook, Marnix Bosch
• Isolation of antigen-specific CD8+ T lymphocytes in vitro and in vivo (7 November, 2013)

  Carina Wehner, Christian Ellinger, Silke Raffegerst, Susanne Wilde, Barbara Mosetter, Dolores J Schendel, Slavoljub Milosevic
• Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer (7 November, 2013)

  John Nemunaitis, Cynthia Bedell, Kevin Klucher, Alex Vo, Sam Whiting
• Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma (7 November, 2013)

  Jon Bjørn, Marco V Donia, Rikke Andersen, Sine R Hadrup, Inge Marie Svane
• T cell receptor affinity and avidity defines antitumor response and autoimmunity in T cell immunotherapy (7 November, 2013)

  Michelle Krogsgaard, Shi Zhong, Karolina Malecek, Laura A Johnson, Zhiya Yu, Eleazar Vega-Saenz de Miera, Farbod Darvishian, Katelyn McGary-Shipper, Kevin Huang, Joshua Boyer, Emily Corse, Yongzhao Shao, Steven A Rosenberg, Nicholas P Restifo, Iman Osman
• Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C (7 November, 2013)

  A K Erbe, Wei Wang, B Grzywacz, E A Ranheim, J A Hank, K Kim, L Carmichael, S Seo, E A Mendonca, Y Song, F Hong, R D Gascoyne, E Paietta, S H Horning, B Kahl, P M Sondel
• Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients (7 November, 2013)

  Holger Lode, Nikolai Siebert, Silke Kietz, Ina Müller, Manfred Schuster, Evelyne Janzek, Susanne Wiederkum, Oliver Mutschlechner, Hans Loibner
• Muci specific IGE to modify myeloid derived cells of the tumor microenvironment (7 November, 2013)

  J Mollick, M Madiyalakan, C Nicodemus
• Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance (7 November, 2013)

  Xin-Feng Chen, Meng Wang, Dong-Li Yue, Jin-Yan Liu, Lan Huang, Feng Li, Song Zhao, Yu Qi, Wei Hu, Xiang-Nan Li, Yi Zhang
• Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab (7 November, 2013) Free

  Jianda Yuan, Jun Zhou, Zhiwan Dong, Sapna Tandon, Deborah Kuk, Katherine S Panageas, Philip Wong, Jedd D Wolchok, F Stephen Hodi
• Frequencies of circulating myeloid derived suppressor cells and dendritic cells in Egyptian patients with chronic Hepatitis C Virus infection undergoing treatment with IFN-α-based therapy (7 November, 2013)

  Mohamed L Salem, Abdel-Aziz A Zidan, Mohamed Abou Senna, Abdel Raouf Abou Al-Azm, Hasan Albatei, Maha Aldemelaawy, Mohamed Attia
• IRF-1 responsiveness to immune cytokines predicts different cancer phenotypes (7 November, 2013) Free

  Daniela Murtas, Dragan Maric, Valeria De Giorgi, Jennifer Reinboth, Andrea Worschech, Patricia Fetsch, Armando Filie, Maria Libera Ascierto, Davide Bedognetti, Qiuzhen Liu, Lorenzo Uccellini, Lotfi Chouchane, Ena Wang, Francesco M Marincola, Sara Tomei
• Expression of cancer testis antigens and its correlation with clinicopathological parameters in hepatocellular carcinoma (7 November, 2013)

  Meng Wang, Xin-feng Chen, Zhi-qin Li, Zhen Zhang, Dong-li Yue, Yan-hong Liu, Dong Jiang, Yu-ling Sun, Yong-fu Zhao, Shu-huan Wu, Jian-sheng Li, Yi Zhang
• Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells (7 November, 2013)

  Aung Naing, Pete Anderson, Sergei Guma, Hsuan-Chu Chien, Lacey MM McQuinn, Joshua P Hein, Ralph G Zinner, Eugenie S Kleinerman, Nancy Gordon
• The effect of chemotherapeutic drugs on human B lymphocytes (7 November, 2013)

  Ali Zirakzadeh, Jin Hu, Johan Kinn, Per Marits, Amir Sherif, Ola Winqvist
• An efficient way to analyze function of immune cells (7 November, 2013) Free

  Zhong Wang, Namyong Kim, Melvin Lye
• Evaluation of TCR amplification in tumor lesions and peripheral blood of renal cell carcinoma patients (7 November, 2013) Free

  Chiara Massa, Harlan Robins, Cindy Desmarais, Dagmar Riemann, Corinna Fahldieck, Paolo Fornara, Barbara Seliger
• Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis (7 November, 2013)

  Magdalena Kovacsovics-Bankowski, Lana Chisholm, Jonna Vercellini, Marka Crittenden, Scot Lary, Brendan Curti, Andrew Weinberg
• Combined radiotherapy and immunotherapy using CPG oligodeoxynucleotides and indolamine 2,3 dioxygenase (IDO) blockade (7 November, 2013)

  Arta M Monjazeb, Steven K Grossenbacher, Gail D Sckisel, Robert Canter, Ellen E Sparger, William Culp, Michael S Kent, William J Murphy
• Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification (7 November, 2013)

  Drew Hotson, Ryan Alvarado, Andrew Conroy, Santosh Putta, Ester Simeone, Assunta Esposito, Mariaelena Capone, Gabriele Madonna, Antonio M Grimaldi, David Rosen, Spencer Liang, Alessandra Cesano, Paolo A Ascierto, Rachael Hawtin
• High fat and alcoholic diets increase hepatic EMH, osteolysis and spontaneous metastases by orthotopic mammary tumors (7 November, 2013) Free

  Anand Dusad, Saraswoti Khadge, Geoffrey M Thiele, Ted R Mikuls, Michael J Duryee, Holly C Britton, Lynell W Klassen, Alicia J Dafferner, Tracy Farrell, Timothy R McGuire, Carlos D Hunter, Karen C Easterling, Barbara J O'Kane, John G Sharp, James E Talmadge
• A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors (7 November, 2013)

  Stephen Ansell, Donald Northfelt, Ian Flinn, Howard Burris, Shira Dinner, Victor Villalobos, Branimir Sikic, Lana Pilja, Michael Yellin, Tibor Keler, Thomas Davis
• DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9 (7 November, 2013)

  Traci L Hilton, Tyler W Hulett, Chistopher Dubay, Rieneke van de Ven, Sandra Aung, Walter J Urba, Hong Ming Hu, Bernard A Fox
• Overcoming immune-cell unresponsiveness in cancer (7 November, 2013)

  Guenther Lametschwandtner, Monika Ermann, Ina Sternberger, Thomas Hesterkamp, Isabella Haslinger, Hannes Mühleisen, Manfred Schuster, Hans Loibner
• Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck (7 November, 2013)

  Tarsem Moudgil, R Bryan Bell, Rom Leidner, Rieneke Van de Ven, Zipei Feng, Michael Affentoulis, Christopher Paustian, Christopher Dubay, Traci L Hilton, Walter J Urba, Hong-Ming Hu, Carlo B Bifulco, Bernard A Fox
• Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro (7 November, 2013) Free

  Reiko Yamada, Kristopher Steward, Gataree Ngarmchamnanrith, Ryan Trinh, Sanjay Khare, Raj Sachdev, Iqbal Grewal, Sherie Morrison, John Timmerman
• High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors (7 November, 2013)

  Fabio Grizzi, Barbara Franceschini, Sonia Di Biccari, Paola Bossi, Maurizio Chiriva-Internati, Soldano Ferrone
• Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors (7 November, 2013)

  Steven L Highfill, Adrienne H Long, Rimas J Orentas, Crystal L Mackall
• Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex (7 November, 2013)

  Andrew Zloza, Joseph R Broucek, Erica J Huelsmann, Tasha Hughes, Howard L Kaufman
• Assessment of the impact of acute inflammation on the anti-cancer responses in a mouse model (7 November, 2013)

  Sohaila M Galal, Mohamed L Salem, Zeinab A Ibrahim
• Interrogating the interactions between myeloid derived suppressor cells and cancer stem cells in glioblastoma (7 November, 2013)

  Balint Otvos, James Finke, Michael Vogelbaum, Justin D Lathia
• Inhibition of tumor growth in vivo by a nanoparticle-based therapeutic cancer vaccine targeting HAAH (7 November, 2013) Free

  Steven Fuller, Solomon Stewart, Michael Lebowitz, Kanam Malhotra, Hossein Ghanbari
• Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy (7 November, 2013)

  Smita K Nair, Gabriel De Leon, David Boczkowski, Robert Schmittling, Weihua Xie, Gerald Archer, John H Sampson, Duane A Mitchell
• Cytomegalovirus containing TRP2 antigen provides protective immunity against the poorly immunogenic B16BL6-D5 melanoma (7 November, 2013)

  Michael Neuberger, Shawn M Jensen, Guangwu Xu, Tameka Smith, Hong-Ming Hu, Ann B Hill, Carlo B Bifulco, Bernard A Fox
• Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma (7 November, 2013)

  Rachel L Sabado, Anna Pavlick, Sacha Gnjatic, Crystal Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, Sylvia Adams, Patrick Ott, Achim Jungbluth, Linda Pan, Ralph Venhaus, Nina Bhardwaj
• Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase (7 November, 2013) Free

  Trine Z Iversen, Lotte Engell-Noerregaard, Eva Ellebaek, Rikke Andersen, Stine K Larsen, Jon Bjoern, Claus Zeyher, Cécile Gouttefangeas, Birte M Thomsen, Bente Holm, Per thor Straten, Anders Mellemgaard, Mads H Andersen, Inge M Svane